n-3 fatty acids and the risk of sudden cardiac death: Emphasis on heart rate variability

Danish Medical Bulletin

Volumn 50, Issue 4, 2003, Pages 347-367

  Christensen, Jeppe Hagstrup ^a  

^a AALBORG UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIARRHYTHMIC AGENT; ANTIINFLAMMATORY AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MONOUNSATURATED FATTY ACID; OMEGA 3 FATTY ACID; POLYUNSATURATED FATTY ACID; SATURATED FATTY ACID; SPIRONOLACTONE; TRIACYLGLYCEROL;

ANTICOAGULANT THERAPY; ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY FAILURE; DEFIBRILLATION; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG EFFECT; DRUG INDICATION; DRUG POTENCY; ENDOTHELIUM CELL; EXPERIMENTAL ANIMAL; HEART INFARCTION PREVENTION; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEART RATE VARIABILITY; HIGH RISK PATIENT; HUMAN; ISCHEMIC HEART DISEASE; LEUKOCYTE ACTIVATION; LEUKOCYTE COUNT; MORTALITY; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; PRIMARY PREVENTION; REVIEW; SUDDEN DEATH; THROMBOCYTE ACTIVATION; THROMBOCYTE COUNT; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; DEATH, SUDDEN, CARDIAC; FATTY ACIDS, OMEGA-3; HEART RATE; HUMANS; SEAFOOD;

EID: 0344876117     PISSN: 09078916     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (373)

1. Christensen JH, Korup E, Aaroe J, Toft E, Moller J, Rasmussen K, Dyerberg J, Schmidt EB. Fish consumption, n-3 fatty acids in cell membranes and heart rate variability in survivors of myocardial infarction with left ventricular dysfunction. Am J Cardiol 1997;79:1670-1673.
2. II. Christensen JH, Gustenhoff P, Korup E, Aarøe J, Toft E, Møller J, Rasmussen K, Dyerberg J, Schmidt EB. The effect of fish oil on heart rate variability in survivors of myocardial infarction: a double blind randomised controlled trial. BMJ 1996;312:677-678.
3. III. Christensen JH, Skou HA, Fog L, Hansen VE, Vesterlund T, Dyerberg J, Toft E, Schmidt EB. Marine n-3 fatty acids, wine intake, and heart rate variability in patients referred for coronary angiography. Circulation 2001;103:651-657.
4. IV. Christensen JH, Aarøe J, Knudsen N, Dideriksen, Dyerberg J, Schmidt EB. Heart rate variability and n-3 polyunsaturated fatty acids in patients with chronic renal failure - a pilot study. Clin Nephrol 1998;49:102-106.
5. V. Christensen JH, Skou HA, Madsen T, Tørring I, Schmidt EB. Heart rate variability and n-3 polyunsaturated fatty acids in patients with diabetes mellitus. J Intern Med 2001;249:545-552.
6. VI. Christensen JH, Christensen MS, Dyerberg J, Schmidt EB. Heart rate variability and fatty acid content of blood cell membranes. A dose-response study with n-3 fatty acids. Am J Clin Nutr 1999;70:331-337.
7. VII. Christensen JH, Christensen MS, Toft E, Dyerberg J, Schmidt EB. Heart rate variability and alpha-linolenic acid in patients at high risk of sudden cardiac death and in healthy volunteers. Nutr Metab Cardiovasc Dis 2000;10:57-61.
8. Bang HO, Dyerberg J, Nielsen AB. Plasma lipid and lipoprotein pattern in Greenlandic West-coast Eskimos. Lancet 1971;1:1143-1145.
9. Bang HO, Dyerberg J. The bleeding tendency in Greenland Eskimos. Dan Med Bull 1980;27:202-205.
10. Bang HO, Dyerberg J, Sinclair HM. The composition of the Eskimo food in north western Greenland. Am J Clin Nutr 1980;33:2657-2661.
11. Dyerberg J, Bang HO, Stoffersen E, Moncada S, Vane JR. Eicosapentaenoic acid and prevention of thrombosis and atherosclerosis? Lancet 1978;2:117-119.
12. Dyerberg J, Bang HO, Hjorne N. Fatty acid composition of the plasma lipids in Greenland Eskimos. Am J Clin Nutr 1975;28:958-966.
13. Dyerberg J, Bang HO. Haemostatic function and platelet polyunsaturated fatty acids in Eskimos. Lancet 1979;2:433-435.
14. Schmidt EB. n-3 fatty acids and the risk of coronary heart disease. Dan Med Bull 1997;44:1-22.
15. Kromann N, Green A. Epidemiological studies in the Upernavik district, Greenland. Incidence of some chronic diseases 1950-1974. Acta Med Scand 1980;208:401-406.
16. Dyerberg J, Bang HO. A hypothesis on the development of acute myocardial infarction in Greenlanders. Scand J Clin Lab Invest Suppl 1982; 161:7-13.
17. Jørgensen KA. Studies on the biological balance between thromboxanes and prostacyclins in relation to the platelet-vessel wall interaction. Dan Med Bull 1982;29:169-197.
18. Kristensen SD. The platelet-vessel wall interaction in experimental atherosclerosis and ischaemic heart disease with special reference to thrombopoiesis. Dan Med Bull 1992;39:110-127.
19. Schmidt EB, Skou HA, Christensen JH, Dyerberg J. N-3 fatty acids from fish and coronary artery disease: implications for public health. Public Health Nutr 2000;3:91-98.
20. Ascherio A, Rimm EB, Stampfer MJ, Giovannucci EL, Willett WC. Dietary intake of marine n-3 fatty acids, fish intake, and the risk of coronary disease among men. N Engl J Med 1995;332:977-982.
21. Guallar E, Hennekens CH, Sacks FM, Willett WC, Stampfer MJ. A prospective study of plasma fish oil levels and incidence of myocardial infarction in U.S. male physicians. J Am Coll Cardiol 1995;25:387-394.
22. Guallar E, Aro A, Jimenez FJ, Martin-Moreno JM, Salminen I, van't Veer P, Kardinaal AF, Gomez-Aracena J, Martin BC, Kohlmeier L, Kark JD, Mazaev VP, Ringstad J, Guillen J, Riemersma RA, Huttunen JK, Thamm M, Kok FJ. Omega-3 fatty acids in adipose tissue and risk of myocardial infarction: the EURAMIC study. Arterioscler Thromb Vasc Biol 1999;19:1111-1118.
23. Kromhout D, Bosschieter EB, de Lezenne CC. The inverse relation between fish consumption and 20-year mortality from coronary heart disease. N Engl J Med 1985;312:1205-1209.
24. Kromhout D, Feskens EJ, Bowles CH. The protective effect of a small amount offish on coronary heart disease mortality in an elderly population. Int J Epidemiol 1995;24:340-345.
25. Morris MC, Manson JE, Rosner B, Buring JE, Willett WC, Hennekens CH. Fish consumption and cardiovascular disease in the physicians' health study: a prospective study. Am J Epidemiol 1995;142:166-175.
26. Stone NJ. Fish consumption, fish oil, lipids, and coronary heart disease. Circulation 1996;94:2337-2340.
27. Tavani A, Pelucchi C, Negri E, Bertuzzi M, La Vecchia C. n-3 Polyunsaturated Fatty Acids, Fish, and Nonfatal Acute Myocardial Infarction. Circulation 2001;104:2269-2272.
28. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet 1999;354:447-455.
29. Burr ML, Fehily AM, Gilbert JF, Rogers S, Holliday RM, Sweetnam PM, Elwood PC, Deadman NM. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet 1989;2:757-761.
30. O'Keefe JH, Jr., Harris WS. From Inuit to implementation: omega-3 fatty acids come of age. Mayo Clin Proc 2000;75:607-614.
31. Schmidt EB, Christensen JH. Long-chained n-3 polyunsaturated fatty acids and coronary heart disease. Curr Opin Clin Metab Care 2000;3: 109-115.
32. Myerburg RJ, Kessler KM, Castellanos A. Sudden cardiac death: epidemiology, transient risk, and intervention assessment. Ann Intern Med 1993;119:1187-1197.
33. Myerburg RJ, Spooner PM. Opportunities for sudden death prevention: directions for new clinical and basic research. Cardiovasc Res 2001;50: 177-185.
34. Zheng ZJ, Croft JB, Giles WH, Mensah GA. Sudden cardiac death in the United States, 1989 to 1998. Circulation 2001;104:2158-2163.
35. Zipes DP, Wellens HJ. Sudden cardiac death. Circulation 1998;98:2334-2351.
36. Pratt CM, Greenway PS, Schoenfeld MH, Hibben ML, Reiffel JA. Exploration of the precision of classifying sudden cardiac death. Implications for the interpretation of clinical trials. Circulation 1996;93:519-524.
37. Epstein AE, Carlson MD, Fogoros RN, Higgins SL, Venditti FJ, Jr. Classification of death in antiarrhythmia trials. J Am Coll Cardiol 1996;27: 433-442.
38. Demirovic J, Myerburg RJ. Epidemiology of sudden coronary death: an overview. Prog Cardiovasc Dis 1994;37:39-48.
39. Holmberg M, Holmberg S, Herlitz J. The problem of out-of-hospital cardiac-arrest prevalence of sudden death in Europe today. Am J Cardiol 1999;83:88D-90D.
40. Olshansky B, Hartz V, Hahn E, Mason J, Weaver MD. Location of death (in-hospital or out-of-hospital) and type of death (arrhythmic, nonarrhythmic, noncardiac) after inducible sustained ventricular tachyarrhythmias after syncope, sustained ventricular tachycardia, or nonfatal cardiac arrest (the ESVEM trial). Am J Cardiol 2000;86:846-851.
41. Bayes dL, Coumel P, Leclercq JF. Ambulatory sudden cardiac death: mechanisms of production of fatal arrhythmia on the basis of data from 157 cases. Am Heart J 1989;117:151-159.
42. Chambless L, Keil U, Dobson A, Mahonen M, Kuulasmaa K, Rajakangas AM, Lowel H, Tunstall-Pedoe H. Population versus clinical view of case fatality from acute coronary heart disease: results from the WHO MONICA Project 1985-1990. Multinational MONItoring of Trends and Determinants in CArdiovascular Disease. Circulation 1997; 96:3849-3859.
43. Myerburg RJ, Mitrani R, Interian A, Jr., Castellanos A. Interpretation of outcomes of antiarrhythmic clinical trials: design features and population impact. Circulation 1998;97:1514-1521.
44. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985;27:335-371.
45. Hjalmarson A, Olsson G. Myocardial infarction. Effects of beta-blockade. Circulation 1991;84:VI101-VI107.
46. Hjalmarson A, Elmfeldt D, Herlitz J, Holmberg S, Malek I, Nyberg G, Ryden L, Swedberg K, Vedin A, Waagstein F, Waldenstrom A, Waldenstrom J, Wedel H, Wilhelmsen L, Wilhelmsson C. Effect on mortality of metoprolol in acute myocardial infarction. A double-blind randomised trial. Lancet 1981;2:823-827.
47. Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. First International Study of Infarct Survival Collaborative Group. Lancet 1986;2:57-66.
48. Herlitz J, Elmfeldt D, Holmberg S, Malek I, Nyberg G, Pennert K, Ryden L, Swedberg K, Vedin A, Waagstein F. Goteborg Metoprolol Trial: mortality and causes of death. Am J Cardiol 1984;53:9D-14D.
49. Herlitz J, Hjalmarson A, Swedberg K, Ryden L, Waagstein F. Effects on mortality during five years after early intervention with metoprolol in suspected acute myocardial infarction. Acta Med Scand 1988;223:227-231.
50. Metoprolol in acute myocardial infarction (MIAMI). A randomised placebo-controlled international trial. The MIAMI Trial Research Group. Eur Heart J 1985;6:199-226.
51. Improvement in prognosis of myocardial infarction by long-term beta-adrenoreceptor blockade using practolol. A multicentre international study. Br Med J 1975;3:735-740.
52. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 1981;304:801-807.
53. Yusuf S, Sleight P, Rossi P, Ramsdale D, Peto R, Furze L, Sterry H, Pearson M, Motwani R, Parish S, Gray R, Bennett D, Bray C. Reduction in infarct size, arrhythmias and chest pain by early intravenous beta blockade in suspected acute myocardial infarction. Circulation 1983;67:132-141.
54. The Beta-Blocker Pooling Project (BBPP): subgroup findings from randomized trials in post infarction patients. The Beta-Blocker Pooling Project Research Group. Eur Heart J 1988;9:8-16.
55. Kennedy HL. Beta blockade, ventricular arrhythmias, and sudden cardiac death. Am J Cardiol 1997;80:29J-34J.
56. Teo KK, Yusuf S, Furberg CD. Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. An overview of results from randomized controlled trials. JAMA 1993;270:1589-1595.
57. Woods KL, Ketley D, Lowy A, Agusti A, Hagn C, Kala R, Karatzas NB, Leizorowicz A, Reikvam A, Schilling J, Seabra-Gomes, R, Vasiliauskas D, Wilhelmsen L. Beta-blockers and antithrombotic treatment for secondary prevention after acute myocardial infarction. Towards an understanding of factors influencing clinical practice. The European Secondary Prevention Study Group. Eur Heart J 1998;19:74-79.
58. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-717.
59. Maggioni AP, Latini R. How to use ACE-inhibitors, beta-blockers, and newer therapies in AMI. Am Heart J 1999;138:183-187.
60. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996;335:1001-1009.
61. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389.
62. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998;339:1349-1357.
63. Randomised trial of intravenous streptokinase, oral aspirin, both, or -neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet 1988;2:349-360.
64. O'Rourke RA. Role of myocardial revascularization in sudden cardiac death. Circulation 1992;85:I112-I117.
65. Holmes DR, Jr., Davis KB, Mock MB, Fisher LD, Gersh BJ, Killip T, III, Pettinger M. The effect of medical and surgical treatment on subsequent sudden cardiac death in patients with coronary artery disease: a report from the Coronary Artery Surgery Study. Circulation 1986;73: 1254-1263.
66. Long-term results of prospective randomised study of coronary artery bypass surgery in stable angina pectoris. European Coronary Surgery Study Group. Lancet 1982;2:1173-1180.
67. Lincoff AM, Califf RM, Anderson KM, Weisman HF, Aguirre FV, Kleiman NS, Harrington RA, Topol EJ. Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IlIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. EPIC Investigators. Evaluation of 7E3 in Preventing Ischemic Complications. J Am Coll Cardiol 1997;30:149-156.
68. Schuhlen H, Hadamitzky M, Walter H, Ulm K, Schomig A. Major benefit from antiplatelet therapy for patients at high risk for adverse cardiac events after coronary Palmaz-Schatz stent placement: analysis of a prospective risk stratification protocol in the Intracoronary Stenting and Antithrombotic Regimen (ISAR) trial. Circulation 1997;95:2015-2021.
69. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. N Engl J Med 1989;321:406-412.
70. Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, Arensberg D, Baker A, Friedman L, Greene HL. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991;324:781-788.
71. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. The Cardiac Arrhythmia Suppression Trial II Investigators. N Engl J Med 1992;327:227-233.
72. Waldo AL, Camm AJ, deRuyter H, Friedman PL, MacNeil DJ, Pauls JF, Pitt B, Pratt CM, Schwartz PJ, Veltri EP. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol. Lancet 1996;348:7-12.
73. Nademanee K, Singh BN, Stevenson WG, Weiss JN. Amiodarone and post-MI patients. Circulation 1993;88:764-774.
74. Burkart F, Pfisterer M, Kiowski W, Follath F, Burckhardt D. Effect of antiarrhythmic therapy on mortality in survivors of myocardial infarction with asymptomatic complex ventricular arrhythmias: Basel Antiarrhythmic Study of Infarct Survival (BASIS). J Am Coll Cardiol 1990; 16:1711-1718.
75. Cairns JA, Connolly SJ, Gent M, Roberts R. Post-myocardial infarction mortality in patients with ventricular premature depolarizations. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Pilot Study. Circulation 1991;84:550-557.
76. Ceremuzynski L, Kleczar E, Krzeminska-Pakula M, Kuch J, Nartowicz E, Smielak-Korombel J, Dyduszynski A, Maciejewicz J, Zaleska T, Lazarczyk-Kedzia E. Effect of amiodarone on mortality after myocardial infarction: a double-blind, placebo-controlled, pilot study. J Am Coll Cardiol 1992;20:1056-1062.
77. Cairns JA, Connolly SJ, Roberts R, Gent M. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators. Lancet 1997;349: 675-682.
78. Julian DG, Camm AJ, Frangin G, Janse MJ, Munoz A, Schwartz PJ, Simon P. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators. Lancet 1997;349:667-674.
79. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials. Amiodarone Trials Meta-Analysis Investigators. Lancet 1997;350:1417-1424.
80. Moss AJ, Hall WJ, Cannom DS, Daubert JP, Higgins SL, Klein H, Levine JH, Saksena S, Waldo AL, Wilber D, Brown MW, Heo M. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med 1996;335: 1933-1940.
81. Bigger JT, Jr. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery. Coronary Artery Bypass Graft (CABG) Patch Trial Investigators. N Engl J Med 1997;337:1569-1575.
82. Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN, Hafley G. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med 1999;341:1882-1890.
83. Klein HU, Reek S. The MUSTT study: evaluating testing and treatment. J Interv Card Electrophysiol 2000;4 Suppl 1:45-50.
84. Glikson M, Friedman PA. The implantable cardioverter defibrillator. Lancet 2001;357:1107-1117.
85. Hlatky MA, Bigger T. Cost-effectiveness of the implantable cardioverter defibrillator? Lancet 2001;357:1817-1818.
86. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. N Engl J Med 1997;337:1576-1583.
87. Connolly SJ, Gent M, Roberts RS, Dorian P, Roy D, Sheldon RS, Mitchell LB, Green MS, Klein GJ, O'Brien B. Canadian implantable defibrillator study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation 2000;101:1297-1302.
88. Siebels J, Kuck KH. Implantable cardioverter defibrillator compared with antiarrhythmic drug treatment in cardiac arrest survivors (the Cardiac Arrest Study Hamburg). Am Heart J 1994;127:1139-1144.
89. Fogoros RN, Elson JJ, Bonnet CA, Fiedler SB, Chenarides JG. Long-term outcome of survivors of cardiac arrest whose therapy is guided by electrophysiologic testing. J Am Coll Cardiol 1992;19:780-788.
90. Winkle RA, Mead RH, Ruder MA, Gaudiani VA, Smith NA, Buch WS, Schmidt P, Shipman T. Long-term outcome with the automatic implantable cardioverter-defibrillator. J Am Coll Cardiol 1989;13:1353-1361.
91. Akhtar M, Avitall B, Jazayeri M, Tchou P, Troup P, Sra J, Axtell K. Role of implantable cardioverter defibrillator therapy in the management of high-risk patients. Circulation 1992;85:1131-1139.
92. Mason JW. A comparison of electrophysiologic testing with Holter monitoring to predict antiarrhythmic-drug efficacy for ventricular tachyarrhythmias. Electrophysiologic Study versus Electrocardiographic Monitoring Investigators. N Engl J Med 1993;329:445-451.
93. Mason JW. A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias. Electrophysiologic Study versus Electrocardiographic Monitoring Investigators. N Engl J Med 1993;329:452-458.
94. Randomized antiarrhythmic drug therapy in survivors of cardiac arrest (the CASCADE Study). The CASCADE Investigators. Am J Cardiol 1993;72:280-287.
95. Schmidt EB, Pedersen JO, Varming K, Ernst E, Jersild C, Grunnet N, Dyerberg J. n-3 fatty acids and leukocyte chemotaxis. Effects in hyperlipidemia and dose-response studies in healthy men. Arterioscler Thromb 1991;11:429-435.
96. Ferrante A, Thong YH. A rapid one-step procedure for purification of mononuclear and polymorphonuclear leukocytes from human blood using a modification of the Hypaque-Ficoll technique. J Immunol Methods 1978;24:389-393.
97. van Kuijk FJ, Thomas DW, Stephens RJ, Dratz EA. Gas chromatography-mass spectrometry method for determination of phospholipid peroxides; I. Transesterification to form methyl esters. J Free Radic Biol Med 1985;1:215-225.
98. Christopherson SW, Glass RL. Preparation of milk fat methyl esters by alcoholysis in an essentially nonalcoholic solution. J Diary Sci 1969;52: 1289-1290.
99. Beynen AC, Katan MB. Rapid sampling and long-term storage of subcutaneous adipose-tissue biopsies for determination of fatty acid composition. Am J Clin Nutr 1985;42:317-322.
100. Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol 1959;37:911-917.
101. Ministry of Agriculture, Fisheries and Food, Food Information Surveillance Sheet 127. Ministry of Agriculture, Fisheries and Food, London, UK. Dietary intake of iodine and fatty acids 1997.
102. Harper CR, Jacobson TA. The fats of life: the role of omega-3 fatty acids in the prevention of coronary heart disease. Arch Intern Med 2001;161: 2185-2192.
103. Sprecher H. Metabolism of highly unsaturated n-3 and n-6 fatty acids. Biochim Biophys Acta 2000;1486:219-231.
104. van Acker BA, Bilo HJ, Popp-Snijders C, van Bronswijk H, Oe PL, Donker AJ. The effect of fish oil on lipid profile and viscosity of erythrocyte suspensions in CAPD patients. Nephrol Dial Transplant 1987; 2:557-561.
105. Lands WE. Biochemistry and physiology of n-3 fatty acids. FASEB J 1992;6:2530-2536.
106. Sprecher H. Interactions between the metabolism of n-3 and n-6 fatty acids. J Intern Med Suppl 1989;225:5-9.
107. Horrobin DF. Omega-6 and omega-3 essential fatty acids in atherosclerosis. Semin Thromb Hemost 1993;19:129-137.
108. Charnock JS, Abeywardena MY, McLennan PL. Comparative changes in the fatty-acid composition of rat cardiac phospholipids after long-term feeding of sunflower seed oil- or tuna fish oil-supplemented diets. Ann Nutr Metab 1986;30:393-406.
109. Pepe S, McLennan PL. Dietary fish oil confers direct antiarrhythmic properties on the myocardium of rats. J Nutr 1996;126:34-42.
110. Saxholt E. Levnedsmiddeltabeller. Levnedsmiddelstyrelsen. Gyldendals Forlag 1996.
111. Hepburn FN, Exler J, Weihrauch JL. Provisional tables on the content of omega-3 fatty acids and other fat components of selected foods. J Am Diet Assoc 1986;86:788-793.
112. Soriguer F, Serna S, Valverde E, Hernando J, Martin-Reyes A, Soriguer M, Pareja A, Tinahones F, Esteva I. Lipid, protein, and calorie content of different Atlantic and Mediterranean fish, shellfish, and molluscs commonly eaten in the south of Spain. Eur J Epidemiol 1997;13:451-463.
113. Burr ML, Fehily AM, Rogers S, Welsby E, King S, Sandham S. Diet and reinfarction trial (DART): design, recruitment, and compliance. Eur Heart J 1989;10:558-567.
114. de Lorgeril M, Renaud S, Mamelle N, Salen P, Martin JL, Monjaud I, Guidollet J, Touboul P, Delaye J. Mediterranean alpha-linolenic acid-rich diet in secondary prevention of coronary heart disease. Lancet 1994;343:1454-1459.
115. Billman GE, Kang JX, Leaf A. Prevention of sudden cardiac death by dietary pure omega-3 polyunsaturated fatty acids in dogs. Circulation 1999;99:2452-2457.
116. Charnock JS. Gamma-linolenic acid provides additional protection against ventricular fibrillation in aged rats fed linoleic acid rich diets. Prostaglandins Leukot Essent Fatty Acids 2000;62:129-134.
117. Kang JX, Leaf A. Protective effects of free polyunsaturated fatty acids on arrhythmias induced by lysophosphatidylcholine or palmitoylcarnitine in neonatal rat cardiac myocytes. Eur J Pharmacol 1996;297:97-106.
118. McLennan PL, Dallimore JA. Dietary canola oil modifies myocardial fatty acids and inhibits cardiac arrhythmias in rats. J Nutr 1995;125: 1003-1009.
119. de Lorgeril M, Salen P, Martin JL, Monjaud I, Delaye J, Mamelle N. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. Circulation 1999;99:779-785.
120. Leaf A. Dietary prevention of coronary heart disease: the Lyon Diet Heart Study. Circulation 1999;99:733-735.
121. Singh RB, Niaz MA, Sharma JP, Kumar R, Rastogi V, Moshiri M. Randomized, double-blind, placebo-controlled trial of fish oil and mustard oil in patients with suspected acute myocardial infarction: the Indian experiment of infarct survival-4. Cardiovasc Drugs Ther 1997;11:485-491.
122. Nilsen DW, Albrektsen G, Landmark K, Moen S, Aarsland T, Woie L. Effects of a high-dose concentrate of n-3 fatty acids or com oil introduced early after an acute myocardial infarction on serum triacylglycerol and HDL cholesterol. Am J Clin Nutr 2001;74:50-56.
123. Luostarinen R, Boberg M, Saldeen T. Fatty acid composition in total phospholipids of human coronary arteries in sudden cardiac death. Atherosclerosis 1993;99:187-193.
124. Siscovick DS, Raghunathan TE, King I, Weinmann S, Wicklund KG, Albright J, Bovbjerg V, Arbogast P, Smith H, Kushi LH. Dietary intake and cell membrane levels of long-chain n-3 polyunsaturated fatty acids and the risk of primary cardiac arrest. JAMA 1995;274:1363-1367.
125. Albert CM, Hennekens CH, O'Donnell CJ, Ajani UA, Carey VJ, Willett WC, Ruskin JN, Manson JE. Fish consumption and risk of sudden cardiac death. JAMA 1998;279:23-28.
126. Hu FB, Stampfer MJ, Manson JE, Rimm EB, Wolk A, Colditz GA, Hennekens CH, Willett WC. Dietary intake of alpha-linolenic acid and risk of fatal ischemic heart disease among women. Am J Clin Nutr 1999; 69:890-897.
127. Connor WE. Alpha-linolenic acid in health and disease. Am J Clin Nutr 1999;69:827-828.
128. Rissanen T, Voutilainen S, Nyyssonen K, Lakka TA, Salonen JT. Fish Oil-Derived Fatty Acids, Docosahexaenoic Acid and Docosapentaenoic Acid, and the Risk of Acute Coronary Events: The Kuopio Ischaemic Heart Disease Risk Factor Study. Circulation 2000;102:2677-2679.
129. Oomen CM, Feskens EJ, Rasanen L, Fidanza F, Nissinen AM, Menotti A, Kok FJ, Kromhout D. Fish consumption and coronary heart disease mortality in Finland, Italy, and The Netherlands. Am J Epidemiol 2000; 151:999-1006.
130. Yuan JM, Ross RK, Gao YT, Yu MC. Fish and shellfish consumption in relation to death from myocardial infarction among men in Shanghai, China. Am J Epidemiol 2001;154:809-816.
131. Charnock JS. Omega-3 polyunsaturated fatty acids and ventricular fibrillation: the possible involvement of eicosanoids. Prostaglandins Leukot Essent Fatty Acids 1999;61:243-247.
132. Kang JX, Leaf A. Prevention of fatal cardiac arrhythmias by polyunsaturated fatty acids. Am J Clin Nutr 2000;71:202S-207S.
133. Leaf A, Kang JX, Xiao YF, Billman GE, Voskuyl RA. The antiarrhythmic and anticonvulsant effects of dietary N-3 fatty acids. J Membr Biol 1999;172:1-11.
134. Leaf A, Kang JX, Xiao YF, Billman GE. n-3 fatty acids in the prevention of cardiac arrhythmias. Lipids 1999;34 Suppl:S187-S189.
135. McLennan P, Howe P, Abeywardena M, Muggli R, Raederstorff D, Mano M, Rayner T, Head R. The cardiovascular protective role of docosahexaenoic acid. Eur J Pharmacol 1996;300:83-89.
136. McLennan PL, Abeywardena MY, Charnock JS. Dietary fish oil prevents ventricular fibrillation following coronary artery occlusion and reperfusion. Am Heart J 1988;116:709-717.
137. Sheard NF. Fish consumption and risk of sudden cardiac death. Nutr Rev 1998;56:177-179.
138. Culp BR, Lands WE, Lucches BR, Pitt B, Romson J. The effect of dietary supplementation of fish oil on experimental myocardial infarction. Prostaglandins 1980;20:1021-1031.
139. Hartog JM, Lamers JM, Verdouw PD. The effects of dietary mackerel oil on plasma and cell membrane lipids, on hemodynamics and cardiac arrhythmias during recurrent acute ischemia in the pig. Basic Res Cardiol 1986;81:567-580.
140. Riemersma RA, Sargent CA. Dietary fish oil and ischaemic arrhythmias. J Intern Med Suppl 1989;225:111-116.
141. McLennan PL, Abeywardena MY, Charnock JS. Influence of dietary lipids on arrhythmias and infarction after coronary artery ligation in rats. Can J Physiol Pharmacol 1985;63:1411-1417.
142. McLennan PL, Abeywardena MY, Charnock JS. The influence of age and dietary fat in an animal model of sudden cardiac death. Aust N Z J Med 1989;19:1-5.
143. McLennan PL, Abeywardena MY, Charnock JS. Reversal of the arrhythmogenic effects of long-term saturated fatty acid intake by dietary n-3 and n-6 polyunsaturated fatty acids. Am J Clin Nutr 1990;51:53-58.
144. Hock CE, Beck LD, Bodine RC, Reibel DK. Influence of dietary n-3 fatty acids on myocardial ischemia and reperfusion. Am J Physiol 1990; 259:H1518-H1526.
145. Sargent CA, Riemersma RA. Polyunsaturated fatty acids and cardiac arrhythmia. Biochem Soc Trans 1990;18:1077-1078.
146. Yang BC, Saldeen TG, Bryant JL, Nichols WW, Mehta JL. Long-term dietary fish oil supplementation protects against ischemia-reperfusion-induced myocardial dysfunction in isolated rat hearts. Am Heart J 1993; 126:1287-1292.
147. Charnock JS. Lipids and cardiac arrhythmia. Prog Lipid Res 1994;33: 355-385.
148. Charnock JS, McLennan PL, Sundram K, Abeywardena MY. Omega-3 PUFA's reduce the vulnerability of the rat heart to ischaemic arrhythmia in the presence of a high intake of saturated animal fat. Nutr Res 1991; 11:1025-1034.
149. McLennan PL. Relative effects of dietary saturated, monounsaturated, and polyunsaturated fatty acids on cardiac arrhythmias in rats. Am J Clin Nutr 1993;57:207-212.
150. McLennan PL, Bridle TM, Abeywardena MY, Charnock JS. Dietary lipid modulation of ventricular fibrillation threshold in the marmoset monkey. Am Heart J 1992;123:1555-1561.
151. McLennan PL, Bridle TM, Abeywardena MY, Charnock JS. Comparative efficacy of n-3 and n-6 polyunsaturated fatty acids in modulating ventricular fibrillation threshold in marmoset monkeys. Am J Clin Nutr 1993;58:666-669.
152. Kinoshita I, Itoh K, Nishida-Nakai M, Hirota H, Otsuji S, Shibata N. Antiarrhythmic effects of eicosapentaenoic acid during myocardial infarction-enhanced cardiac microsomal (Ca(2+)-Mg2+)-ATPase activity. Jpn Circ J 1994;58:903-912.
153. Billman GE, Hallaq H, Leaf A. Prevention of ischemia-induced ventricular fibrillation by omega 3 fatty acids. Proc Natl Acad Sci USA 1994;91:4427-4430.
154. Billman GE, Kang JX, Leaf A. Prevention of ischemia-induced cardiac sudden death by n-3 polyunsaturated fatty acids in dogs. Lipids 1997;32:1161-1168.
155. Billman GE, Leaf A. The effects of omega-3 fatty acids on the heart rate variability response to exercise. Physiologist 2000;43:338.
156. Spector AA, Mathur SN, Kaduce TL, Hyman BT. Lipid nutrition and metabolism of cultured mammalian cells. Prog Lipid Res 1980;19:155-186.
157. Spector AA, Yorek MA. Membrane lipid composition and cellular function. J Lipid Res 1985;26:1015-1035.
158. Spector AA. Essentiality of fatty acids. Lipids 1999;34 Suppl:S1-S3.
159. Leifert WR, McMurchie EJ, Saint DA. Inhibition of cardiac sodium currents in adult rat myocytes by n-3 polyunsaturated fatty acids. J Physiol (Lond) 1999;520 Pt 3:671-679.
160. Lund EK, Harvey LJ, Ladha S, Clark DC, Johnson IT. Effects of dietary fish oil supplementation on the phospholipid composition and fluidity of cell membranes from human volunteers. Ann Nutr Metab 1999;43:290-300.
161. Hashimoto M, Hossain S, Yamasaki H, Yazawa K, Masumura S. Effects of eicosapentaenoic acid and docosahexaenoic acid on plasma membrane fluidity of aortic endothelial cells. Lipids 1999;34:1297-1304.
162. Lutz M, Alvarado J, Barraza P, Bonilla S, Luna L. Effects of dietary oils and cholesterol supplement on fluidity and enzyme activities of liver microsomes in the rat. Lipids 1999;34 Suppl:S119.
163. Berlin E, Bhathena SJ, McClure D, Peters RC. Dietary menhaden and com oils and the red blood cell membrane lipid composition and fluidity in hyper- and normocholesterolemic miniature swine. J Nutr 1998; 128:1421-1428.
164. Hagve TA, Woldseth B, Brox J, Narce M, Poisson JP. Membrane fluidity and fatty acid metabolism in kidney cells from rats fed purified eicosapentaenoic acid or purified docosahexaenoic acid. Scand J Clin Lab Invest 1998;58:187-194.
165. Vognild E, Elvevoll EO, Brox J, Olsen RL, Barstad H, Aursand M, Osterud B. Effects of dietary marine oils and olive oil on fatty acid composition, platelet membrane fluidity, platelet responses, and serum lipids in healthy humans. Lipids 1998;33:427-436.
166. Stillwell W, Jenski LJ, Crump FT, Ehringer W. Effect of docosahexaenoic acid on mouse mitochondrial membrane properties. Lipids 1997; 32:497-506.
167. Brown ER, Subbaiah PV. Differential effects of eicosapentaenoic acid and docosahexaenoic acid on human skin fibroblasts. Lipids 1994;29: 825-829.
168. Moncada S, Needleman P, Bunting S, Vane JR. Prostaglandin endoperoxide and thromboxane generating systems and their selective inhibition. Prostaglandins 1976;12:323-335.
169. Moncada S, Gryglewski R, Bunting S, Vane JR. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 1976;263:663-665.
170. Hamberg M, Samuelsson B. Prostaglandin endoperoxides. Novel transformations of arachidonic acid in human platelets. Proc Natl Acad Sci USA 1974;71:3400-3404.
171. Knapp HR, Reilly IA, Alessandrini P, Fitzgerald GA. In vivo indexes of platelet and vascular function during fish-oil administration in patients with atherosclerosis. N Engl J Med 1986;314:937-942.
172. Knapp HR, Salem N, Jr. Formation of PGI3 in the rat during dietary fish oil supplementation. Prostaglandins 1989;38:509-521.
173. Knapp HR. Omega-3 fatty acids, endogenous prostaglandins, and blood pressure regulation in humans. Nutr Rev 1989;47:301-313.
174. Fischer S, Weber PC. Prostaglandin 13 is formed in vivo in man after dietary eicosapentaenoic acid. Nature 1984;307:165-168.
175. Kelley DS, Rudolph IL. Effect of individual fatty acids of omega-6 and omega-3 type on human immune status and role of eicosanoids. Nutrition 2000;16:143-145.
176. James MJ, Gibson RA, Cleland LG. Dietary polyunsaturated fatty acids and inflammatory mediator production. Am J Clin Nutr 2000;71:343S-348S.
177. Parratt JR, Coker SJ, Wainwright CL. Eicosanoids and susceptibility to ventricular arrhythmias during myocardial ischaemia and reperfusion. J Mol Cell Cardiol 1987;19 Suppl 5:55-66.
178. Coker SJ. Further evidence that thromboxane exacerbates arrhythmias: effects of UK38485 during coronary artery occlusion and reperfusion in anaesthetized greyhounds. J Mol Cell Cardiol 1984;16:633-641.
179. Coker SJ, Parratt JR. The effects of nafazatrom on arrhythmias and prostanoid release during coronary artery occlusion and reperfusion in anaesthetized greyhounds. J Mol Cell Cardiol 1984;16:43-52.
180. Coker SJ, Parratt JR. Effects of dazoxiben on arrhythmias and ventricular fibrillation induced by coronary artery occlusion and reperfusion in anaesthetised greyhounds. Br J Clin Pharmacol 1983;15 Suppl 1:87S-95S.
181. Araki H, Lefer AM. Role of prostacyclin in the preservation of ischemic myocardial tissue in the perfused cat heart. Circ Res 1980;47:757-763.
182. Abeywardena MY, Fischer S, Schweer H, Charnock JS. In vivo formation of metabolites of prostaglandins 12 and 13 in the marmoset monkey (Callithrix jacchus) following dietary supplementation with tuna fish oil. Biochim Biophys Acta 1989;1003:161-166.
183. Abeywardena MY, McLennan PL, Charnock JS. Changes in myocardial eicosanoid production following long-term dietary lipid supplementation in rats. Am J Clin Nutr 1991;53:1039S-1041S.
184. Abeywardena MY, McLennan PL, Charnock JS. Differences between in vivo and in vitro production of eicosanoids following long-term dietary fish oil supplementation in the rat. Prostaglandins Leukot Essent Fatty Acids 1991;42:159-165.
185. Abeywardena MY, McLennan PL, Charnock JS. Differential effects of dietary fish oil on myocardial prostaglandin 12 and thromboxane A2 production. Am J Physiol 1991;260:H379-H385.
186. Abeywardena MY, Charnock JS. Dietary lipid modification of myocardial eicosanoids following ischemia and reperfusion in the rat. Lipids 1995;30:1151-1156.
187. Charnock JS. Dietary fats and cardiac arrhythmia in primates. Nutrition 1994;10:161-169.
188. Nair SS, Leitch JW, Falconer J, Garg ML. Prevention of cardiac arrhythmia by dietary (n-3) polyunsaturated fatty acids and their mechanism of action. J Nutr 1997;127:383-393.
189. Riemersma RA. Raised plasma non-esterified fatty acids (NEFA) during ischaemia: implications for arrhythmias. Basic Res Cardiol 1987;82 Suppl 1:177-186.
190. Oliver MF, Opie LH. Effects of glucose and fatty acids on myocardial ischaemia and arrhythmias. Lancet 1994;343:155-158.
191. Opie LH. Sympathetic stimulation of ischemic myocardium: role of plasma free fatty acids and potassium. J Cardiovasc Pharmacol 1988;12 Suppl 1:S31-S38.
192. Nayler WG. The heart cell: some metabolic aspects of cardiac arrhythmias. Acta Med Scand Suppl 1981;647:17-31.
193. Kang JX, Leaf A. Effects of long-chain polyunsaturated fatty acids on the contraction of neonatal rat cardiac myocytes. Proc Natl Acad Sci U S A 1994;91:9886-9890.
194. Kang JX, Leaf A. Prevention and termination of beta-adrenergic agonist-induced arrhythmias by free polyunsaturated fatty acids in neonatal rat cardiac myocytes. Biochem Biophys Res Commun 1995;208:629-636.
195. Kang JX, Leaf A. Antiarrhythmic effects of polyunsaturated fatty acids - recent studies. Circulation 1996;94:1774-1780.
196. Weylandt KH, Kang JX, Leaf A. Polyunsaturated fatty acids exert antiarrhythmic actions as free acids rather than in phospholipids. Lipids 1996;31:977-982.
197. Nair SS, Leitch J, Garg ML. Specific modifications of phosphatidylinositol and nonesterified fatty acid fractions in cultured porcine cardiomyocytes supplemented with n-3 polyunsaturated fatty acids. Lipids 1999;34:697-704.
198. Nair SS, Leitch J, Falconer J, Garg ML. Cardiac (n-3) non-esterified fatty acids are selectively increased in fish oil-fed pigs following myocardial ischemia. J Nutr 1999;129:1518-1523.
199. Leaf A, Kang JX, Xiao YF, Billman GE. Dietary n-3 fatty acids in the prevention of cardiac arrhythmias. Curr Opin Clin Nutr Metab Care 1998;1:225-228.
200. Leaf A, Kang JX, Xiao YF, Billman GE, Voskuyl RA. Functional and electrophysiologic effects of polyunsaturated fatty acids on exictable tissues: heart and brain. Prostaglandins Leukot Essent Fatty Acids 1999; 60:307-312.
201. Kang JX, Leaf A. Evidence that free polyunsaturated fatty acids modify Na+ channels by directly binding to the channel proteins. Proc Natl Acad Sci U S A 1996;93:3542-3546.
202. Hallaq H, Smith TW, Leaf A. Modulation of dihydropyridine-sensitive calcium channels in heart cells by fish oil fatty acids. Proc Natl Acad Sci U S A 1992;89:1760-1764.
203. Xiao YF, Kang JX, Morgan JP, Leaf A. Blocking effects of polyunsaturated fatty acids on Na+ channels of neonatal rat ventricular myocytes. Proc Natl Acad Sci U S A 1995;92:11000-11004.
204. Garratt JC, McEnvoy MP, Owen DG. Blockade of two voltage-dependent potassium channels, mkv1.1 and mKv1.2, by docosahexaenoic acid. Eur J Pharmacol 1996;314:393-396.
205. Xiao YF, Gomez AM, Morgan JP, Lederer WJ, Leaf A. Suppression of voltage-gated L-type Ca2+ currents by polyunsaturated fatty acids in adult and neonatal rat ventricular myocytes. Proc Natl Acad Sci U S A 1997;94:4182-4187.
206. Negretti N, Perez MR, Walker D, O'Neill SC. Inhibition of sarcoplasmic reticulum function by polyunsaturated fatty acids in intact, isolated myocytes from rat ventricular muscle. J Physiol 2000;523 Pt 2:367-375.
207. Skuladottir GV, Johannsson M. Inotropic response of rat heart papillary muscle to alpha 1- and beta-adrenoceptor stimulation in relation to dietary n-6 and n-3 poly-unsaturated fatty acids (PUFA) and age. Pharmacol Toxicol 1997;80:85-90.
208. de Jonge HW, Dekkers DH, Bastiaanse EM, Bezstarosti K, van der LA, Lamers JM. Eicosapentaenoic acid incorporation in membrane phospholipids modulates receptor-mediated phospholipase C and membrane fluidity in rat ventricular myocytes in culture. J Mol Cell Cardiol 1996; 28:1097-1108.
209. Reithmann C, Scheininger C, Bulgan T, Werdan K. Exposure to the n-3 poly-unsaturated fatty acid docosahexaenoic acid impairs alpha 1-adrenoceptor-mediated contractile responses and inositol phosphate formation in rat cardiomyocytes. Naunyn Schmiedebergs Arch Pharmacol 1996;354:109-119.
210. Grynberg A, Fournier A, Sergiel JP, Athias P. Membrane docosahexaenoic acid vs. eicosapentaenoic acid and the beating function of the cardiomyocyte and its regulation through the adrenergic receptors. Lipids 1996;31 Suppl:S205-S210.
211. Grynberg A, Fournier A, Sergiel JP, Athias P. Effect of docosahexaenoic acid and eicosapentaenoic acid in the phospholipids of rat heart muscle cells on adrenoceptor responsiveness and mechanism. J Mol Cell Cardiol 1995;27:2507-2520.
212. Jacobsen AN, Du XJ, Lambert KA, Dart AM, Woodcock EA. Arrhythmogenic action of thrombin during myocardial reperfusion via release of inositol 1,4,5-triphosphate. Circulation 1996;93:23-26.
213. Anderson KE, Du XJ, Sinclair AJ, Woodcock EA, Dart AM. Dietary fish oil prevents reperfusion Ins(1,4,5)P3 release in rat heart: possible antiarrhythmic mechanism. Am J Physiol 1996;271:H1483-H1490.
214. Jahangiri A, Leifert WR, Patten GS, McMurchie EJ. Termination of asynchronous contractile activity in rat atrial myocytes by n-3 polyunsaturated fatty acids. Mol Cell Biochem 2000;206:33-41.
215. Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Circulation 1996;93:1043-1065.
216. Kleiger RE, Bigger JT, Bosner MS, Chung MK, Cook JR, Rolnitzky LM, Steinman R, Fleiss JL. Stability over time of variables measuring heart rate variability in normal subjects. Am J Cardiol 1991;68:626-630.
217. Bigger JT, Jr., Fleiss JL, Steinman RC, Rolnitzky LM, Kleiger RE, Rottman JN. Correlations among time and frequency domain measures of heart period variability two weeks after acute myocardial infarction. Am J Cardiol 1992;69:891-898.
218. Kleiger RE, Stein PK, Bosner MS, Rottman JN. Time domain measurements of heart rate variability. Cardiol Clin 1992;10:487-498.
219. Stein PK, Kleiger RE. Insights from the study of heart rate variability. Annu Rev Med 1999;50:249-261.
220. Billman GE, Schwartz PJ, Stone HL. Baroreceptor reflex control of heart rate: a predictor of sudden cardiac death. Circulation 1982;66:874-880.
221. Schwartz PJ, Billman GE, Stone HL. Autonomic mechanisms in ventricular fibrillation induced by myocardial ischemia during exercise in dogs with healed myocardial infarction. An experimental preparation for sudden cardiac death. Circulation 1984;69:790-800.
222. Schwartz PJ, La Rovere MT, Vanoli E. Autonomic nervous system and sudden cardiac death. Experimental basis and clinical observations for post-myocardial infarction risk stratification. Circulation 1992;85:177-191.
223. Barron HV, Lesh MD. Autonomic nervous system and sudden cardiac death. J Am Coll Cardiol 1996;27:1053-1060.
224. Schwartz PJ. The autonomic nervous system and sudden death. Eur Heart J 1998;19 Suppl F:F72-F80.
225. Airaksinen KE. Autonomic mechanisms and sudden death after abrupt coronary occlusion. Ann Med 1999;31:240-245.
226. Lombardi F, Makikallio TH, Myerburg RJ, Huikuri HV. Sudden cardiac death: role of heart rate variability to identify patients at risk. Cardiovasc Res 2001;50:210-217.
227. Sandrone G, Mortara A, Torzillo D, La Rovere MT, Malliani A, Lombardi F. Effects of beta blockers (atenolol or metoprolol) on heart rate variability after acute myocardial infarction. Am J Cardiol 1994;74:340-345.
228. Mølgaard H, Mickley H, Pless P, Bjerregaard P, Møller M. Effects of metoprolol on heart rate variability in survivors of acute myocardial infarction. Am J Cardiol 1993;71:1357-1359.
229. Zhang YH, Song YC, Zhu J, Hu TH, Wan LL. Effects of enalapril on heart rate variability in patients with congestive heart failure. Am J Cardiol 1995;76:1045-1048.
230. Binkley PF, Haas GJ, Starling RC, Nunziata E, Hatton PA, Leier CV, Cody RJ. Sustained augmentation of parasympathetic tone with angiotensin-converting enzyme inhibition in patients with congestive heart failure. J Am Coll Cardiol 1993;21:655-661.
231. Goldsmith RL, Bigger JT, Bloomfield DM, Krum H, Steinman RC, Sackner-Bernstein J, Packer M. Long-term carvedilol therapy increases parasympathetic nervous system activity in chronic congestive heart failure. Am J Cardiol 1997;80:1101-1104.
232. Hohnloser SH, Klingenheben T, Zabel M, Just H. Effect of sotalol on heart rate variability assessed by Holter monitoring in patients with ventricular arrhythmias. Am J Cardiol 1993;72:67A-71A.
233. Pedretti RF, Colombo E, Sarzi BS, Caru B. Effect of thrombolysis on heart rate variability and life-threatening ventricular arrhythmias in survivors of acute myocardial infarction. J Am Coll Cardiol 1994;23:19-26.
234. Zabel M, Klingenheben T, Hohnloser SH. Changes in autonomic tone following thrombolytic therapy for acute myocardial infarction: assessment by analysis of heart rate variability. J Cardiovasc Electrophysiol 1994;5:211-218.
235. Zuanetti G, Neilson JM, Latini R, Santoro E, Maggioni AP, Ewing DJ. Prognostic significance of heart rate variability in post-myocardial infarction patients in the fibrinolytic era. The GISSI-2 results. Gruppo Italiano per lo Studio della Sopravvivenza nell' Infarto Miocardico. Circulation 1996;94:432-436.
236. Fauchier L, Babuty D, Autret ML, Poret P, Cosnay P, Fauchier JP. Effect of flecainide on heart rate variability in subjects without coronary artery disease or congestive heart failure. Cardiovasc Drugs Ther 1998;12: 483-486.
237. Zuanetti G, Latini R, Neilson JM, Schwartz PJ, Ewing DJ. Heart rate variability in patients with ventricular arrhythmias: effect of antiarrhythmic drugs. Antiarrhythmic Drug Evaluation Group (ADEG). J Am Coll Cardiol 1991;17:604-612.
238. Stein PK, Rottman JN, Kuru T, Kleiger RE. Effect of moricizine on heart rate variability in normal subjects. Int J Cardiol 1995;48:59-65.
239. La Rovere MT, Bigger JT, Jr., Marcus FI, Mortara A, Schwartz PJ. Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction. ATRAMI (Autonomic Tone and Reflexes After Myocardial Infarction) Investigators. Lancet 1998; 351:478-484.
240. Dambrink JH, Tuininga YS, van Gilst WH, Peels KH, Lie KI, Kingma JH. Association between reduced heart rate variability and left ventricular dilatation in patients with a first anterior myocardial infarction. CATS Investigators. Captopril and Thrombolysis Study. Br Heart J 1994;72:514-520.
241. Siscovick DS, Raghunathan T, King I, Weinmann S, Bovbjerg VE, Kushi L, Cobb LA, Copass MK, Psaty BM, Lemaitre R, Retzlaff B, Knopp RH. Dietary intake of long-chain n-3 polyunsaturated fatty acids and the risk of primary cardiac arrest. Am J Clin Nutr 2000;71:208S-212S.
242. Mølgaard H, Sørensen KE, Bjerregaard P. Circadian variation and influence of risk factors on heart rate variability in healthy subjects. Am J Cardiol 1991;68:777-784.
243. Mølgaard H, Hermansen K, Bjerregaard P. Spectral components of short-term RR interval variability in healthy subjects and effects of risk factors. Eur Heart J 1994;15:1174-1183.
244. Gudbjarnason S. Dynamics of n-3 and n-6 fatty acids in phospholipids of heart muscle. J Intern Med Suppl 1989;225:117-128.
245. Bigger JT, Jr., Fleiss JL, Rolnitzky LM, Steinman RC, Schneider WJ. Time course of recovery of heart period variability after myocardial infarction. J Am Coll Cardiol 1991;18:1643-1649.
246. Bigger JT, Jr., Fleiss JL, Steinman RC, Rolnitzky LM, Kleiger RE, Rottman JN. Frequency domain measures of heart period variability and mortality after myocardial infarction. Circulation 1992;85:164-171.
247. Casolo GC, Stroder P, Signorini C, Calzolari F, Zucchini M, Balli E, Sulla A, Lazzerini S. Heart rate variability during the acute phase of myocardial infarction. Circulation 1992;85:2073-2079.
248. Copie X, Hnatkova K, Staunton A, Fei L, Camm AJ, Malik M. Predictive power of increased heart rate versus depressed left ventricular ejection fraction and heart rate variability for risk stratification after myocardial infarction. Results of a two-year follow-up study. J Am Coll Cardiol 1996;27:270-276.
249. Fetsch T, Reinhardt L, Makijarvi M, Bocker D, Block M, Borggrefe M, Breithardt G. Heart rate variability in time domain after acute myocardial infarction. Clin Sci (Colch) 1996;91 Suppl:136-140.
250. Hartikainen JE, Malik M, Staunton A, Poloniecki J, Camm AJ. Distinction between arrhythmic and nonarrhythmic death after acute myocardial infarction based on heart rate variability, signal-averaged electrocardiogram, ventricular arrhythmias and left ventricular ejection fraction. J Am Coll Cardiol 1996;28:296-304.
251. Hohnloser SH, Klingenheben T, Zabel M, Li YG. Heart rate variability used as an arrhythmia risk stratifier after myocardial infarction. Pacing Clin Electrophysiol 1997;20:2594-2601.
252. Kleiger RE, Miller JP, Bigger JT, Jr., Moss AJ. Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. Am J Cardiol 1987;59:256-262.
253. Lanza GA, Galeazzi M, Guido V, Lucente M, Bellocci F, Zecchi P, Maseri A. Additional predictive value of heart rate variability in high-risk patients surviving an acute myocardial infarction. Cardiologia 1999;44:249-253.
254. Lanza GA, Guido V, Galeazzi MM, Mustilli M, Natali R, Ierardi C, Milici C, Burzotta F, Pasceri V, Tomassini F, Lupi A, Maseri A. Prognostic role of heart rate variability in patients with a recent acute myocardial infarction. Am J Cardiol 1998;82:1323-1328.
255. Malik M, Camm AJ, Janse MJ, Julian DG, Frangin GA, Schwartz PJ. Depressed heart rate variability identifies postinfarction patients who might benefit from prophylactic treatment with amiodarone: a substudy of EMIAT (The European Myocardial Infarct Amiodarone Trial). J Am Coll Cardiol 2000;35:1263-1275.
256. Quintana M, Storck N, Lindblad LE, Lindvall K, Ericson M. Heart rate variability as a means of assessing prognosis after acute myocardial infarction. A 3-year follow-up study. Eur Heart J 1997;18:789-797.
257. Vaishnav S, Stevenson R, Marchant B, Lagi K, Ranjadkvalan K, Timmis AD. Relation between heart rate variability early after acute myocardial infarction and long-term mortality. Am J Cardiol 1994;73:653-657.
258. Voss A, Hnatkova K, Wessel N, Kurths J, Sander A, Schirdewan A, Camm AJ, Malik M. Multiparametric analysis of heart rate variability used for risk stratification among survivors of acute myocardial infarction. Pacing Clin Electrophysiol 1998;21:186-192.
259. Bigger JT, Jr., Fleiss JL, Rolnitzky LM, Steinman RC. Frequency domain measures of heart period variability to assess risk late after myocardial infarction. J Am Coll Cardiol 1993;21:729-736.
260. Rich MW, Saini JS, Kleiger PE, Carney RM, teVelde A, Freedland KE. Correlation of heart rate variability with clinical and angiographic variables and late mortality after coronary angiography. Am J Cardiol 1988; 62:714-717.
261. Algra A, Tijssen JG, Roelandt JR, Pool J, Lubsen J. Heart rate variability from 24-hour electrocardiography and the 2-year risk for sudden death. Circulation 1993;88:180-185.
262. Farrell TG, Bashir Y, Cripps T, Malik M, Poloniecki J, Bennett ED, Ward DE, Camm AJ. Risk stratification for arrhythmic events in postinfarction patients based on heart rate variability, ambulatory electrocardiographic variables and the signal-averaged electrocardiogram. J Am Coll Cardiol 1991;18:687-697.
263. Hohnloser SH, Klingenheben T, Zabel M, Schopperl M, Mauss O. Prevalence, characteristics and prognostic value during long-term follow-up of nonsustained ventricular tachycardia after myocardial infarction in the thrombolytic era. J Am Coll Cardiol 1999;33:1895-1902.
264. Pruvot E, Thonet G, Vesin JM, van Melle G, Seidl K, Schmidinger H, Brachmann J, Jung W, Hoffmann E, Tavernier R, Block M, Podczeck A, Fromer M. Heart rate dynamics at the onset of ventricular tachyarrhythmias as retrieved from implantable cardioverter-defibrillators in patients with coronary artery disease. Circulation 2000;101:2398-2404.
265. Hardarson T, Kristinsson A, Skuladottir G, Asvaldsdottir H, Snorrason SP. Cod liver oil does not reduce ventricular extrasystoles after myocardial infarction. J Intern Med 1989;226:33-37.
266. Christensen JH, Gustenhoff P, Ejlersen E, Jessen T, Korup E, Rasmussen K, Dyerberg J, Schmidt EB. n-3 fatty acids and ventricular extrasystoles in patients with ventricular tachyarrhythmias. Nutr Res 1995;15:1-8.
267. Sellmayer A, Witzgall H, Lorenz RL, Weber PC. Effects of dietary fish oil on ventricular premature complexes. Am J Cardiol 1995;76:974-977.
268. Christensen JH, Gustenhoff P, Korup E, Aaroe J, Toft E, Moller J, Rasmussen K, Dyerberg J, Schmidt EB. n-3 fatty acids and ventricular arrhythmias in post-myocardial infarction patients with a low ejection fraction. In: Kristensen SD, Schmidt EB, De Caterina R, Endres S, eds. n-3 fatty acids: prevention and treatment in vascular disease. Verona: Bi & Gi Publishers, Springer-Verlag; 1995:107-114.
269. Grønbæk M. Wine and mortality. Biofactors 1997;6:377-383.
270. Grønbæk M, Sørensen TI. Alcohol consumption and risk of coronary heart disease. Studies suggest that wine has additional effect to that of ethanol. BMJ 1996;313:365.
271. Grønbæk M, Deis A, Sørensen TI, Becker U, Schnohr P, Jensen G. Mortality associated with moderate intakes of wine, beer, or spirits. BMJ 1995;310:1165-1169.
272. Rimm EB, Klatsky A, Grobbee D, Stampfer MJ. Review of moderate alcohol consumption and reduced risk of coronary heart disease: is the effect due to beer, wine, or spirits. BMJ 1996;312:731-736.
273. Fagrell B, de Faire U, Bondy S, Criqui M, Gaziano M, Grønbæ k M, Jackson R, Klatsky A, Salonen J, Shaper AG. The effects of light to moderate drinking on cardiovascular diseases. J Intern Med 1999;246:331-340.
274. Grønbæk M. Type of alcohol and mortality from cardiovascular disease. Food Chem Toxicol 1999;37:921-924.
275. Tjønneland A, Grønbæk M, Stripp C, Overvad K. Wine intake and diet in a random sample of 48763 Danish men and women. Am J Clin Nutr 1999;69:49-54.
276. Marckmann P, Lassen A, Haraldsdottir J, Sandstrøm B. Biomarkers of habitual fish intake in adipose tissue. Am J Clin Nutr 1995;62:956-959.
277. Agelink MW, Malessa R, Weisser U, Lemmer W, Zeit T, Majewski T, Klieser E. Alcoholism, peripheral neuropathy (PNP) and cardiovascular autonomic neuropathy (CAN). J Neurol Sci 1998;161:135-142.
278. Rajan I, Murthy PJ, Ramakrishnan AG, Gangadhar BN, Janakiramaiah N. Heart rate variability as an index of cue reactivity in alcoholics. Biol Psychiatry 1998;43:544-546.
279. Murata K, Araki S, Yokoyama K, Sata F, Yamashita K, Ono Y. Autonomic neurotoxicity of alcohol assessed by heart rate variability. J Auton Nerv Syst 1994;48:105-111.
280. Malpas SC, Whiteside EA, Maling TJ. Heart rate variability and cardiac autonomic function in men with chronic alcohol dependence. Br Heart J 1991;65:84-88.
281. Weise F, Muller D, Krell D, Kielstein V, Koch RD. Heart rate variability in chronic alcoholics: a follow-up study. Drug Alcohol Depend 1986; 17:365-368.
282. Weise F, Muller D, Krell D, Kielstein V, Koch RD. Heart rate variability of chronic alcoholics in withdrawal and abstinence. Clin Neurol Neurosurg 1985;87:95-98.
283. de Lemos JA, Hillis LD. Diagnosis and management of coronary artery disease in patients with end-stage renal disease on hemodialysis. J Am Soc Nephrol 1996;7:2044-2054.
284. Wing AJ, Broyer M, Brunner FP, Brynger H, Challah S, Donckerwolcke RA, Gretz N, Jacobs C, Kramer P, Selwood NH. Combined report on regular dialysis and transplantation in Europe, XIII, 1982. Proc Eur Dial Transplant Assoc 1983;20:2-75.
285. Wing AJ, Brunner FP, Brynger H, Jacobs C, Kramer P, Selwood NH, Gretz N. Cardiovascular-related causes of death and the fate of patients with renovascular disease. Contrib Nephrol 1984;41:306-311.
286. Valderrabano F, Berthoux FC, Jones EH, Mehls O. Report on management of renal failure in Europe, XXV, 1994 end stage renal disease and dialysis report. The EDTA-ERA Registry. European Dialysis and Transplant Association-European Renal Association. Nephrol Dial Transplant 1996;11 Suppl 1:2-21.
287. Hathaway DK, Cashion AK, Milstead EJ, Winsett RP, Cowan PA, Wicks MN, Gaber AO. Autonomic dysregulation in patients awaiting kidney transplantation. Am J Kidney Dis 1998;32:221-229.
288. Kurata C, Uehara A, Sugi T, Ishikawa A, Fujita K, Yonemura K, Hishida A, Ishikawa K, Tawarahara K, Shouda S, Mikami T. Cardiac autonomic neuropathy in patients with chronic renal failure on hemodialysis. Nephron 2000;84:312-319.
289. Rostand SG, Brunzell JD, Cannon RO, III, Victor RG. Cardiovascular complications in renal failure. J Am Soc Nephrol 1991;2:1053-1062.
290. Boero R, Pignataro A, Ferro M, Quarello F. Sympathetic nervous system and chronic renal failure. Clin Exp Hypertens 2001;23:69-75.
291. Erem C, Kulan K, Tuncer C, Bostan M, Mocan Z, Komsuoglu B. Cardiac arrhythmias in patients on maintenance hemodialysis. Acta Cardiol 1997;52:25-36.
292. Multicentre, cross-sectional study of ventricular arrhythmias in chronically haemo-dialysed patients. Gruppo Emodialisi e Patologie Cardiovasculari. Lancet 1988;2:305-309.
293. Narula AS, Jha V, Bali HK, Sakhuja V, Sapru RP. Cardiac arrhythmias and silent myocardial ischemia during hemodialysis. Ren Fail 2000;22: 355-368.
294. Tamura K, Tsuji H, Nishiue T, Yajima I, Higashi T, Iwasaka T. Determinants of heart rate variability in chronic hemodialysis patients. Am J Kidney Dis 1998;31:602-606.
295. Thomson BJ, McAreavey D, Neilson JM, Winney RJ, Ewing DJ. Heart rate variability and cardiac arrhythmias in patients with chronic renal failure. Clin Auton Res 1991;1:131-133.
296. Ravenswaaij-Arts CM, Kollee LA, Hopman JC, Stoelinga GB, van Geijn HP. Heart rate variability. Ann Intern Med 1993;118:436-447.
297. Chertow GM, Normand SL, Silva LR, McNeil BJ. Survival after acute myocardial infarction in patients with end-stage renal disease: results from the cooperative cardiovascular project. Am J Kidney Dis 2000;35: 1044-1051.
298. Hayano J, Takahashi H, Toriyama T, Mukai S, Okada A, Sakata S, Yamada A, Ohte N, Kawahara H. Prognostic value of heart rate variability during long-term follow-up in chronic haemodialysis patients with end-stage renal disease. Nephrol Dial Transplant 1999;14:1480-1488.
299. Yildiz A, Sever MS, Demirel S, Akkaya V, Turk S, Turkmen A, Ecder T, Ark E. Improvement of uremic autonomic dysfunction after renal transplantation: a heart rate variability study. Nephron 1998;80:57-60.
300. Strano S, De Castro S, Urani C, Ferrucci A, Marcheselli A, Poli L, Berloco P, Calcagnini G, Jr., Cerutti S, Cortesini R. Power spectrum analysis of heart rate variability following kidney transplantation. Transplant Proc 1993;25:2600-2601.
301. Deligiannis A, Kouidi E, Tourkantonis A. Effects of physical training on heart rate variability in patients on hemodialysis. Am J Cardiol 1999;84: 197-202.
302. Sweny P. Use of dietary fish oils in renal allograft recipients with chronic vascular rejection. Transplant Proc 1993;25:2089-2091.
303. van der Heide JJ, Bilo HJ, Donker JM, Wilmink JM, Tegzess AM. Effect of dietary fish oil on renal function and rejection in cyclosporine-treated recipients of renal transplants. N Engl J Med 1993;329:769-773.
304. Donadio JV, Jr., Bergstralh EJ, Offord KP, Spencer DC, Holley KE. A controlled trial of fish oil in IgA nephropathy. Mayo Nephrology Collaborative Group. N Engl J Med 1994;331:1194-1199.
305. De Caterina R, Endres S, Kristensen SD, Schmidt EB. n-3 fatty acids and renal diseases. Am J Kidney Dis 1994;24:397-415.
306. Donadio JV, Jr. Use of fish oil to treat patients with immunoglobulin a nephropathy. Am J Clin Nutr 2000;71:373S-375S.
307. Reardon M, Malik M. Changes in heart rate variability with age. Pacing Clin Electrophysiol 1996;19:1863-1866.
308. Ziegler D, Piolot R, Strassburger K, Lambeck H, Dannehl K. Normal ranges and reproducibility of statistical, geometric, frequency domain, and non-linear measures of 24-hour heart rate variability. Horm Metab Res 1999;31:672-679.
309. Tsuji H, Venditti FJ, Jr., Manders ES, Evans JC, Larson MG, Feldman CL, Levy D. Determinants of heart rate variability. J Am Coll Cardiol 1996;28:1539-1546.
310. Gaba MK, Gaba S, Clark LT. Cardiovascular disease in patients with diabetes: clinical considerations. J Assoc Acad Minor Phys 1999;10:15-22.
311. Liebl A, Neiss A, Spannheimer A, Reitberger U, Wieseler B, Stammer H, Goertz A. Complications, co-morbidity, and blood glucose control in type 2 diabetes mellitus patients in Germany - results from the CODE-2 study. Exp Clin Endocrinol Diabetes 2002;110:10-16.
312. Mak KH, Topol EJ. Emerging concepts in the management of acute myocardial infarction in patients with diabetes mellitus. J Am Coll Cardiol 2000;35:563-568.
313. Goldberg RB. Cardiovascular disease in diabetic patients. Med Clin North Am 2000;84:81-93, viii.
314. McGuire DK, Granger CB. Diabetes and ischemic heart disease. Am Heart J 1999;138:366-375.
315. Weston PJ, Gill GV. Is undetected autonomic dysfunction responsible for sudden death in Type 1 diabetes mellitus? The 'dead in bed' syndrome revisited. Diabet Med 1999;16:626-631.
316. Ziegler D. Diabetic cardiovascular autonomic neuropathy: prognosis, diagnosis and treatment. Diabetes Metab Rev 1994;10:339-383.
317. Balkau B, Jouven X, Ducimetiere P, Eschwege E. Diabetes as a risk factor for sudden death. Lancet 1999;354:1968-1969.
318. Jouven X, Desnos M, Guerot C, Ducimetiere P. Predicting sudden death in the population: the Paris Prospective Study I. Circulation 1999;99: 1978-1983.
319. Malik M. Heart rate variability. Curr Opin Cardiol 1998;13:36-44.
320. Stein PK, Bosner MS, Kleiger RE, Conger BM. Heart rate variability: a measure of cardiac autonomic tone. Am Heart J 1994;127:1376-138.
321. Mølgaard H, Christensen PD, Sørensen KE, Christensen CK, Mogensen CE. Association of 24-h cardiac parasympathetic activity and degree of nephropathy in IDDM patients. Diabetes 1992;41:812-817.
322. Mølgaard H, Christensen PD, Hermansen K, Sørensen KE, Christensen CK, Mogensen CE. Early recognition of autonomic dysfunction in microalbuminuria: significance for cardiovascular mortality in diabetes mellitus? Diabetologia 1994;37:788-796.
323. Burger AJ, Weinrauch LA, D'Elia JA, Aronson D. Effect of glycemic control on heart rate variability in type 1 diabetic patients with cardiac autonomic neuropathy. Am J Cardiol 1999;84:687-691.
324. Howorka K, Pumprla J, Haber P, Koller-Strametz J, Mondrzyk J, Schabmann A. Effects of physical training on heart rate variability in diabetic patients with various degrees of cardiovascular autonomic neuropathy. Cardiovasc Res 1997;34:206-214.
325. Ziegler D, Schatz H, Conrad F, Gries FA, Ulrich H, Reichel G. Effects of treatment with the antioxidant alpha-lipoic acid on cardiac autonomic neuropathy in NIDDM patients. A 4-month randomized controlled multicenter trial (DEKAN Study). Deutsche Kardiale Autonome Neuropathie. Diabetes Care 1997;20:369-373.
326. Athyros VG, Didangelos TP, Karamitsos DT, Papageorgiou AA, Boudoulas H, Kontopoulos AG. Long-term effect of converting enzyme inhibition on circadian
327. Fisher M. Diabetes and myocardial infarction. Baillieres Clin Endocrinol Metab 1999;13:331-343.
328. Cruickshank JM. Beta-blockers continue to surprise us. Eur Heart J 2000;21:354-364.
329. Herlitz J, Malmberg K. How to improve the cardiac prognosis for diabetes. Diabetes Care 1999;22 Suppl 2:B89-B96.
330. Passa P. Reducing the cardiovascular consequences of diabetes mellitus. Diabet Med 1998;15 Suppl 4:S69-S72.
331. MacDonald TM, Butler R, Newton RW, Morris AD. Which drugs benefit diabetic patients for secondary prevention of myocardial infarction? DARTS/MEMO Collaboration. Diabet Med 1998;15:282-289.
332. Gerbi A, Maixent JM, Barbey O, Jamme I, Pierlovisi M, Coste T, Pieroni G, Nouvelot A, Vague P, Raccah D. Alterations of Na,K-ATPase isoenzymes in the rat diabetic neuropathy: protective effect of dietary supplementation with n-3 fatty acids. J Neurochem 1998;71:732-740.
333. Gerbi A, Maixent JM, Ansaldi JL, Pierlovisi M, Coste T, Pelissier JF, Vague P, Raccah D. Fish oil supplementation prevents diabetes-induced nerve conduction velocity and neuroanatomical changes in rats. J Nutr 1999;129:207-213.
334. Okuda Y, Mizutani M, Ogawa M, Sone H, Asano M, Asakura Y, Isaka M, Suzuki S, Kawakami Y, Field JB, Yamashita K. Long-term effects of eicosapentaenoic acid on diabetic peripheral neuropathy and serum lipids in patients with type II diabetes mellitus. J Diabetes Complications 1996;10:280-287.
335. Luo J, Rizkalla SW, Vidal H, Oppert JM, Colas C, Boussairi A, Guerre-Millo M, Chapuis AS, Chevalier A, Durand G, Slama G. Moderate intake of n-3 fatty acids for 2 months has no detrimental effect on glucose metabolism and could ameliorate the lipid profile in type 2 diabetic men. Results of a controlled study. Diabetes Care 1998;21:717-724.
336. Sirtori CR, Paoletti R, Mancini M, Crepaldi G, Manzato E, Rivellese A, Pamparana F, Stragliotto E. N-3 fatty acids do not lead to an increased diabetic risk in patients with hyperlipidemia and abnormal glucose tolerance. Italian Fish Oil Multicenter Study. Am J Clin Nutr 1997;65: 1874-1881.
337. Tibblin G, Eriksson C-G, Bjurö T, Georgescu D, Svärdsudd C. Heart rate and heart rate variability a risk factor for the development of ischaemic heart disease (IHD) in the "men born in 1913 study" - a ten years follow-up. Med Sci Cardiovasc Sys Soc Occup 1975;3:95.
338. Dekker JM, Schouten EG, Klootwijk P, Pool J, Swenne CA, Kromhout D. Heart rate variability from short electrocardiographic recordings predicts mortality from all causes in middle-aged and elderly men. The Zutphen Study. Am J Epidemiol 1997;145:899-908.
339. Dekker JM, Crow RS, Folsom AR, Hannan PJ, Liao D, Swenne CA, Schouten EG. Low heart rate variability in a 2-minute rhythm strip predicts risk of coronary heart disease and mortality from several causes: the ARIC Study. Atherosclerosis Risk In Communities. Circulation 2000;102:1239-1244.
340. Tsuji H, Larson MG, Venditti FJ, Jr., Manders ES, Evans JC, Feldman CL, Levy D. Impact of reduced heart rate variability on risk for cardiac events. The Framingham Heart Study. Circulation 1996;94:2850-2855.
341. Tsuji H, Venditti FJ, Jr., Manders ES, Evans JC, Larson MG, Feldman CL, Levy D. Reduced heart rate variability and mortality risk in an elderly cohort. The Framingham Heart Study. Circulation 1994;90:878-883.
342. Mølgaard H, Sørensen KE, Bjerregaard P. Attenuated 24-h heart rate variability in apparently healthy subjects, subsequently suffering sudden cardiac death. Clin Auton Res 1991;1:233-237.
343. Karason K, Mølgaard H, Wikstrand J, Sjøstrøm L. Heart rate variability in obesity and the effect of weight loss. Am J Cardiol 1999;83:1242-1247.
344. Piccirillo G, Vetta F, Fimognari FL, Ronzoni S, Lama J, Cacciafesta M, Marigliano V. Power spectral analysis of heart rate variability in obese subjects: evidence of decreased cardiac sympathetic responsiveness. Int J Obes Relat Metab Disord 1996;20:825-829.
345. Hirsch J, Leibel RL, Mackintosh R, Aguirre A. Heart rate variability as a measure of autonomic function during weight change in humans. Am J Physiol 1991;261:R1418-R1423.
346. Mølgaard H. 24-hour heart rate variability - methodology and clinical aspects. Thesis/Dissertation 1995:41-43.
347. Grimsgaard S, Bonaa KH, Hansen JB, Myhre ES. Effects of highly purified eicosa-pentaenoic acid and docosahexaenoic acid on hemodynamics in humans. Am J Clin Nutr 1998;68:52-59.
348. Minami M, Kimura S, Endo T, Hamaue N, Hirafuji M, Togashi H, Matsumoto M, Yoshioka M, Saito H, Watanabe S, Kobayashi T, Okuyama H. Dietary docosa-hexaenoic acid increases cerebral acetylcholine levels and improves passive avoidance performance in stroke-prone spontaneously hypertensive rats. Pharmacol Biochem Behav 1997;58: b1123-1129.
349. Das UN. Beneficial effect(s) of n-3 fatty acids in cardiovascular diseases: but, why and how? Prostaglandins Leukot Essent Fatty Acids 2000;63:351-362.
350. Lauritzen L, Hansen HS, Jorgensen MH, Michaelsen KF. The essentiality of long chain n-3 fatty acids in relation to development and function of the brain and retina. Prog Lipid Res 2001;40:1-94.
351. Youdim KA, Martin A, Joseph JA. Essential fatty acids and the brain: possible health implications. Int J Dev Neurosci 2000;18:383-399.
352. Hjalmarson A. Cardioprotection with beta-adrenoceptor blockers. Does lipophilicity matter? Basic Res Cardiol 2000;95 Suppl 1:141-145.
353. Lavoie KL, Fleet RP. The impact of depression on the course and outcome of coronary artery disease: review for cardiologists. Can J Cardiol 2000;16:653-662.
354. Barrick CB. Sad, glad, or mad hearts? Epidemiological evidence for a causal relationship between mood disorders and coronary artery disease. J Affect Disord 1999;53:193-201.
355. Glassman AH, Shapiro PA. Depression and the course of coronary artery disease. Am J Psychiatry 1998;155:4-11.
356. Carney RM, Freedland KE, Sheline YI, Weiss ES. Depression and coronary heart disease: a review for cardiologists. Clin Cardiol 1997;20: 196-200.
357. Cohen H, Matar MA, Kaplan Z, Kotler M. Power spectral analysis of heart rate variability in psychiatry. Psychother Psychosom 1999;68:59-66.
358. Malaspina D, Bruder G, Dalack GW, Storer S, Van Kammen M, Amador X, Glassman A, Gorman J. Diminished cardiac vagal tone in schizophrenia: associations to brain laterality and age of onset. Biol Psychiatry 1997;41:612-617.
359. Yeragani VK, Balon R, Pohl R, Ramesh C. Depression and heart rate variability. Biol Psychiatry 1995;38:768-770.
360. Yeragani VK. Heart rate and blood pressure variability: implications for psychiatric research. Neuropsychobiology 1995;32:182-191.
361. Carney RM, Rich MW, teVelde A, Saini J, Clark K, Freedland KE. The relationship between heart rate, heart rate variability and depression in patients with coronary artery disease. J Psychosom Res 1988;32:159-164.
362. Carney RM, Saunders RD, Freedland KE, Stein P, Rich MW, Jaffe AS. Association of depression with reduced heart rate variability in coronary artery disease. Am J Cardiol 1995;76:562-564.
363. Stein PK, Carney RM, Freedland KE, Skala JA, Jaffe AS, Kleiger RE, Rottman JN. Severe depression is associated with markedly reduced heart rate variability in patients with stable coronary heart disease. J Psychosom Res 2000;48:493-500.
364. Carney RM, Blumenthal JA, Stein PK, Watkins L, Catellier D, Berkman LF, Czajkowski SM, O'Connor C, Stone PH, Freedland KE. Depression, heart rate variability, and acute myocardial infarction. Circulation 2001;104:2024-2028.
365. Edwards R, Peet M, Shay J, Horrobin D. Omega-3 polyunsaturated fatty acid levels in the diet and in red blood cell membranes of depressed patients. J Affect Disord 1998;48:149-155.
366. Fenton WS, Hibbeln J, Knable M. Essential fatty acids, lipid membrane abnormalities, and the diagnosis and treatment of schizophrenia. Biol Psychiatry 2000;47:8-21.
367. Stoll AL, Locke CA, Marangell LB, Severus WE. Omega-3 fatty acids and bipolar disorder: a review. Prostaglandins Leukot Essent Fatty Acids 1999;60:329-337.
368. Tanskanen A, Hibbeln JR, Tuomilehto J, Uutela A, Haukkala A, Viinamaki H, Lehtonen J, Vartiainen E. Fish consumption and depressive symptoms in the general population in Finland. Psychiatr Serv 2001;52: 529-531.
369. Freeman MP. Omega-3 fatty acids in psychiatry: a review. Ann Clin Psychiatry 2000;12:159-165.
370. Stoll AL, Severus WE, Freeman MP, Rueter S, Zboyan HA, Diamond E, Cress KK, Marangell LB. Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial. Arch Gen Psychiatry 1999;56:407-412.
371. Hibbeln JR, DePetrillo P, Champoux JD, Higley JD, Lindell S, Shannon C, Suomi S, Salem Jr N. Improvements in heart rate variability among adolescent rhesus monkeys fed formula supplemented with DHA and AA as infants: neuropsychiatric implications. 91st AOCS Annual Meeting & Expo Abstracts. www.aocs.org/meetings/abstract/am2000fa.htm
372. Horrocks LA, Yeo YK. Health benefits of docosahexaenoic acid (DHA). Pharmacol Res 1999;40:211-225.
373. Bigger JT, Jr., El Sherif T. Polyunsaturated fatty acids and cardiovascular events: a fish tale. Circulation 2001;103:623-625.